Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • AJNR Case Collection
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • Special Collections
    • Spinal CSF Leak Articles (Jan 2020-June 2024)
    • 2024 AJNR Journal Awards
    • Most Impactful AJNR Articles
  • Multimedia
    • AJNR Podcast
    • AJNR Scantastics
    • Video Articles
  • For Authors
    • Submit a Manuscript
    • Author Policies
    • Fast publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Manuscript Submission Guidelines
    • Imaging Protocol Submission
    • Submit a Case for the Case Collection
  • About Us
    • About AJNR
    • Editorial Board
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Other Publications
    • ajnr

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • AJNR Case Collection
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • Special Collections
    • Spinal CSF Leak Articles (Jan 2020-June 2024)
    • 2024 AJNR Journal Awards
    • Most Impactful AJNR Articles
  • Multimedia
    • AJNR Podcast
    • AJNR Scantastics
    • Video Articles
  • For Authors
    • Submit a Manuscript
    • Author Policies
    • Fast publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Manuscript Submission Guidelines
    • Imaging Protocol Submission
    • Submit a Case for the Case Collection
  • About Us
    • About AJNR
    • Editorial Board
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

Welcome to the new AJNR, Updated Hall of Fame, and more. Read the full announcements.


AJNR is seeking candidates for the position of Associate Section Editor, AJNR Case Collection. Read the full announcement.

 

Research ArticleBrain Tumor Imaging

Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction

Nicholas S. Cho, Francesco Sanvito, Viên Lam Le, Sonoko Oshima, Ashley Teraishi, Jingwen Yao, Donatello Telesca, Catalina Raymond, Whitney B. Pope, Phioanh L. Nghiemphu, Albert Lai, Timothy F. Cloughesy, Noriko Salamon and Benjamin M. Ellingson
American Journal of Neuroradiology February 2024, 45 (2) 188-197; DOI: https://doi.org/10.3174/ajnr.A8094
Nicholas S. Cho
aFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California
bDepartment of Radiological Sciences (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., W.B.P., N.S., B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
cDepartment of Bioengineering (N.S.C., V.L.L., B.M.E.), Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, Los Angeles, California
dMedical Scientist Training Program (N.S.C.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicholas S. Cho
Francesco Sanvito
aFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California
bDepartment of Radiological Sciences (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., W.B.P., N.S., B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francesco Sanvito
Viên Lam Le
aFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California
bDepartment of Radiological Sciences (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., W.B.P., N.S., B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
cDepartment of Bioengineering (N.S.C., V.L.L., B.M.E.), Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonoko Oshima
aFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California
bDepartment of Radiological Sciences (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., W.B.P., N.S., B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashley Teraishi
aFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California
bDepartment of Radiological Sciences (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., W.B.P., N.S., B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ashley Teraishi
Jingwen Yao
aFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California
bDepartment of Radiological Sciences (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., W.B.P., N.S., B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jingwen Yao
Donatello Telesca
eDepartment of Biostatistics (D.T.), Fielding School of Public Health, University of California Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catalina Raymond
aFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California
bDepartment of Radiological Sciences (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., W.B.P., N.S., B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Catalina Raymond
Whitney B. Pope
bDepartment of Radiological Sciences (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., W.B.P., N.S., B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Whitney B. Pope
Phioanh L. Nghiemphu
fUCLA Neuro-Oncology Program (P.L.N., A.L., T.F.C.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
gDepartment of Neurology (P.L.N., A.L., T.F.C.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Phioanh L. Nghiemphu
Albert Lai
fUCLA Neuro-Oncology Program (P.L.N., A.L., T.F.C.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
gDepartment of Neurology (P.L.N., A.L., T.F.C.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Albert Lai
Timothy F. Cloughesy
fUCLA Neuro-Oncology Program (P.L.N., A.L., T.F.C.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
gDepartment of Neurology (P.L.N., A.L., T.F.C.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Timothy F. Cloughesy
Noriko Salamon
bDepartment of Radiological Sciences (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., W.B.P., N.S., B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Noriko Salamon
Benjamin M. Ellingson
aFrom the UCLA Brain Tumor Imaging Laboratory (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., B.M.E.), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, California
bDepartment of Radiological Sciences (N.S.C., F.S., V.L.L., S.O., A.T., J.Y., C.R., W.B.P., N.S., B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
cDepartment of Bioengineering (N.S.C., V.L.L., B.M.E.), Henry Samueli School of Engineering and Applied Science, University of California, Los Angeles, Los Angeles, California
hDepartment of Neurosurgery (B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
iDepartment of Psychiatry and Biobehavioral Sciences (B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Benjamin M. Ellingson
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

References

  1. 1.↵
    1. Louis DN,
    2. Perry A,
    3. Wesseling P, et al
    . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076
    CrossRefPubMed
  2. 2.↵
    1. Yan H,
    2. Parsons DW,
    3. Jin G, et al
    ; IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73 doi:10.1056/NEJMoa0808710 pmid:19228619
    CrossRefPubMedWeb of Science
  3. 3.↵
    1. Miller JJ,
    2. Gonzalez Castro LN,
    3. McBrayer S, et al
    . Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol 2023;25:4–25 doi:10.1093/neuonc/noac207 pmid:36239925
    CrossRefPubMed
  4. 4.↵
    1. Mellinghoff IK,
    2. Lu M,
    3. Wen PY, et al
    . Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative Phase 1 trial. Nat Med 2023;29:615–22 doi:10.1038/s41591-022-02141-2 pmid:36823302
    CrossRefPubMed
  5. 5.↵
    1. Mellinghoff IK,
    2. van den Bent MJ,
    3. Blumenthal DT, et al
    ; INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med 2023;389:589–601 doi:10.1056/NEJMoa2304194 pmid:37272516
    CrossRefPubMed
  6. 6.↵
    1. Patel SH,
    2. Poisson LM,
    3. Brat DJ, et al
    . T2–FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res 2017;23:6078–85 doi:10.1158/1078-0432.CCR-17-0560 pmid:28751449
    Abstract/FREE Full Text
  7. 7.↵
    1. Broen MP,
    2. Smits M,
    3. Wijnenga MM, et al
    . The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol 2018;20:1393–99 doi:10.1093/neuonc/noy048 pmid:29590424
    CrossRefPubMed
  8. 8.↵
    1. Lasocki A,
    2. Buckland ME,
    3. Drummond KJ, et al
    . Conventional MRI features can predict the molecular subtype of adult grade 2–3 intracranial diffuse gliomas. Neuroradiology 2022;64:2295–305 doi:10.1007/s00234-022-02975-0 pmid:35606654
    CrossRefPubMed
  9. 9.↵
    1. Corell A,
    2. Ferreyra Vega S,
    3. Hoefling N, et al
    . The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study. BMC Cancer 2020;20:450 doi:10.1186/s12885-020-06951-w pmid:32434559
    CrossRefPubMed
  10. 10.↵
    1. Juratli TA,
    2. Tummala SS,
    3. Riedl A, et al
    . Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. J Neurooncol 2019;141:327–35 doi:10.1007/s11060-018-03034-6 pmid:30536195
    CrossRefPubMed
  11. 11.↵
    1. Kinoshita M,
    2. Arita H,
    3. Takahashi M, et al
    . Impact of inversion time for FLAIR acquisition on the T2-FLAIR mismatch detectability for IDH-mutant, non-CODEL astrocytomas. Front Oncol 2020;10:596448 doi:10.3389/fonc.2020.596448 pmid:33520709
    CrossRefPubMed
  12. 12.↵
    1. Deguchi S,
    2. Oishi T,
    3. Mitsuya K, et al
    . Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas. Sci Rep 2020;10:10113 doi:10.1038/s41598-020-67244-7 pmid:32572107
    CrossRefPubMed
  13. 13.↵
    1. Jain R,
    2. Johnson DR,
    3. Patel SH, et al
    . “Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas. Neuro Oncol 2020;22:936–43 doi:10.1093/neuonc/noaa041 pmid:32064507
    CrossRefPubMed
  14. 14.↵
    1. Li M,
    2. Ren X,
    3. Chen X, et al
    . Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma. Eur Radiol 2022;32:3869–79 doi:10.1007/s00330-021-08500-w pmid:35079884
    CrossRefPubMed
  15. 15.↵
    1. Lee MD,
    2. Patel SH,
    3. Mohan S, et al
    ; ReSPOND Consortium. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium. Neuroradiology 2023;65:1343–52 doi:10.1007/s00234-023-03196-9 pmid:37468750
    CrossRefPubMed
  16. 16.↵
    1. Mohammed S,
    2. Ravikumar V,
    3. Warner E, et al
    . Quantifying T2-FLAIR mismatch using geographically weighted regression and predicting molecular status in lower-grade gliomas. AJNR Am J Neuroradiol 2022;43:33–39 doi:10.3174/ajnr.A7341 pmid:34764084
    Abstract/FREE Full Text
  17. 17.↵
    1. Lee MK,
    2. Park JE,
    3. Jo Y, et al
    . Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign. Eur Radiol 2020;30:844–54 doi:10.1007/s00330-019-06395-2 pmid:31446467
    CrossRefPubMed
  18. 18.↵
    1. Yamashita S,
    2. Takeshima H,
    3. Kadota Y, et al
    . T2-fluid-attenuated inversion recovery mismatch sign in lower grade gliomas: correlation with pathological and molecular findings. Brain Tumor Pathol 2022;39:88–98 doi:10.1007/s10014-022-00433-6 pmid:35482260
    CrossRefPubMed
  19. 19.↵
    1. Ellingson BM,
    2. Kim HJ,
    3. Woodworth DC, et al
    . Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 2014;271:200–10 doi:10.1148/radiol.13131305 pmid:24475840
    CrossRefPubMedWeb of Science
  20. 20.↵
    1. Calabrese E,
    2. Villanueva-Meyer JE,
    3. Rudie JD, et al
    . The University of California San Francisco Preoperative Diffuse Glioma MRI Dataset. Radiol Artif Intell 2022;4:e220058 doi:10.1148/ryai.220058 pmid:36523646
    CrossRefPubMed
  21. 21.↵
    1. Calabrese E,
    2. Villanueva-Meyer JE,
    3. Rudie JD, et al
    . The University of California San Francisco Preoperative Diffuse Glioma MRI Dataset. Radiology Artif Intell 2022;4:e220058 doi:10.1148/ryai.220058 pmid:36523646
    CrossRefPubMed
  22. 22.↵
    1. Clark K,
    2. Vendt B,
    3. Smith K, et al
    . The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging 2013;26:1045–57 doi:10.1007/s10278-013-9622-7 pmid:23884657
    CrossRefPubMedWeb of Science
  23. 23.↵
    1. Cho NS,
    2. Hagiwara A,
    3. Sanvito F, et al
    . A multi-reader comparison of normal-appearing white matter normalization techniques for perfusion and diffusion MRI in brain tumors. Neuroradiology 2023;65:559–68 doi:10.1007/s00234-022-03072-y pmid:36301349
    CrossRefPubMed
  24. 24.↵
    1. Kline CN,
    2. Joseph NM,
    3. Grenert JP, et al
    . Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro Oncol 2017;19:699–709 doi:10.1093/neuonc/now254 pmid:28453743
    CrossRefPubMed
  25. 25.↵
    1. Lai A,
    2. Kharbanda S,
    3. Pope WB, et al
    . Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 2011;29:4482–90 doi:10.1200/JCO.2010.33.8715 pmid:22025148
    Abstract/FREE Full Text
  26. 26.↵
    1. Fischl B
    . FreeSurfer. Neuroimage 2012;62:774–81 doi:10.1016/j.neuroimage.2012.01.021 pmid:22248573
    CrossRefPubMedWeb of Science
  27. 27.↵
    1. Smith SM,
    2. Jenkinson M,
    3. Woolrich MW, et al
    . Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(Suppl 1):S208–19 doi:10.1016/j.neuroimage.2004.07.051 pmid:15501092
    CrossRefPubMedWeb of Science
  28. 28.↵
    1. Isensee F,
    2. Schell M,
    3. Pflueger I, et al
    . Automated brain extraction of multisequence MRI using artificial neural networks. Hum Brain Mapp 2019;40:4952–64 doi:10.1002/hbm.24750 pmid:31403237
    CrossRefPubMed
  29. 29.↵
    1. Hagiwara A,
    2. Oughourlian TC,
    3. Cho NS, et al
    . Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro Oncol 2022;24:1020–28 doi:10.1093/neuonc/noab276 pmid:34865129
    CrossRefPubMed
  30. 30.↵
    1. Cox RW
    . AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 1996;29:162–73 doi:10.1006/cbmr.1996.0014 pmid:8812068
    CrossRefPubMedWeb of Science
  31. 31.↵
    1. Ellingson BM,
    2. Harris RJ,
    3. Woodworth DC, et al
    . Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro Oncol 2017;19:89–98 doi:10.1093/neuonc/now187 pmid:27580889
    CrossRefPubMed
  32. 32.↵
    1. Viera AJ,
    2. Garrett JM
    . Understanding interobserver agreement: the kappa statistic. Fam Med 2005;37:360–63 pmid:15883903
    PubMedWeb of Science
  33. 33.↵
    1. Foltyn M,
    2. Nieto Taborda KN,
    3. Neuberger U, et al
    . T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology. Neurooncol Adv 2020;2:vdaa004 doi:10.1093/noajnl/vdaa004 pmid:32642675
    CrossRefPubMed
  34. 34.↵
    1. Wagner MW,
    2. Nobre L,
    3. Namdar K, et al
    . T2-FLAIR mismatch sign in pediatric low-grade glioma. AJNR Am J Neuroradiol 2023;44:841–45 doi:10.3174/ajnr.A7916 pmid:37348970
    Abstract/FREE Full Text
  35. 35.↵
    1. Mancini L,
    2. Casagranda S,
    3. Gautier G, et al
    . CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing. Eur J Nucl Med Mol Imaging 2022;49:2377–91 doi:10.1007/s00259-022-05676-1 pmid:35029738
    CrossRefPubMed
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 45 (2)
American Journal of Neuroradiology
Vol. 45, Issue 2
1 Feb 2024
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
Nicholas S. Cho, Francesco Sanvito, Viên Lam Le, Sonoko Oshima, Ashley Teraishi, Jingwen Yao, Donatello Telesca, Catalina Raymond, Whitney B. Pope, Phioanh L. Nghiemphu, Albert Lai, Timothy F. Cloughesy, Noriko Salamon, Benjamin M. Ellingson
Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction
American Journal of Neuroradiology Feb 2024, 45 (2) 188-197; DOI: 10.3174/ajnr.A8094

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
Quantifying T2-FLAIR Mismatch in Diffuse Gliomas
Nicholas S. Cho, Francesco Sanvito, Viên Lam Le, Sonoko Oshima, Ashley Teraishi, Jingwen Yao, Donatello Telesca, Catalina Raymond, Whitney B. Pope, Phioanh L. Nghiemphu, Albert Lai, Timothy F. Cloughesy, Noriko Salamon, Benjamin M. Ellingson
American Journal of Neuroradiology Feb 2024, 45 (2) 188-197; DOI: 10.3174/ajnr.A8094
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS:
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSIONS
    • Footnotes
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Crossref (4)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • The Interplay between Glioblastoma Cells and Tumor Microenvironment: New Perspectives for Early Diagnosis and Targeted Cancer Therapy
    Assunta Virtuoso, Giuseppa D’Amico, Federica Scalia, Ciro De Luca, Michele Papa, Grazia Maugeri, Velia D’Agata, Celeste Caruso Bavisotto, Agata Grazia D’Amico
    Brain Sciences 2024 14 4
  • Utilizing Radiomics of Peri‐Lesional Edema in T2‐FLAIR Subtraction Digital Images to Distinguish High‐Grade Glial Tumors From Brain Metastasis
    Emin Demirel, Okan Dilek
    Journal of Magnetic Resonance Imaging 2025 61 4
  • Deep learning-based quantification of T2-FLAIR mismatch sign: extending IDH mutation prediction in adult-type diffuse lower-grade glioma
    Young Hun Jeon, Kyu Sung Choi, Kyung Hoon Lee, Seong Yun Jeong, Ji Ye Lee, Taehyuk Ham, Inpyeong Hwang, Roh-Eul Yoo, Koung Mi Kang, Tae Jin Yun, Seung Hong Choi, Ji-hoon Kim, Chul-Ho Sohn
    European Radiology 2025
  • Diffusion MRI is superior to quantitative T2-FLAIR mismatch in predicting molecular subtypes of human non-enhancing gliomas
    Nicholas S. Cho, Francesco Sanvito, Viên Lam Le, Sonoko Oshima, Ashley Teraishi, Jingwen Yao, Donatello Telesca, Catalina Raymond, Whitney B. Pope, Phioanh L. Nghiemphu, Albert Lai, Noriko Salamon, Timothy F. Cloughesy, Benjamin M. Ellingson
    Neuroradiology 2024 66 12

More in this TOC Section

  • Temporal Evolution of Vestibular schwannoma
  • CE MRI for Brain Metastasis Detection
  • Standardized rCBV in Brain Metastases
Show more BRAIN TUMOR IMAGING

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editors Choice
  • Fellow Journal Club
  • Letters to the Editor

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

Special Collections

  • Special Collections

Resources

  • News and Updates
  • Turn around Times
  • Submit a Manuscript
  • Author Policies
  • Manuscript Submission Guidelines
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Submit a Case
  • Become a Reviewer/Academy of Reviewers
  • Get Peer Review Credit from Publons

Multimedia

  • AJNR Podcast
  • AJNR SCANtastic
  • Video Articles

About Us

  • About AJNR
  • Editorial Board
  • Not an AJNR Subscriber? Join Now
  • Alerts
  • Feedback
  • Advertise with us
  • Librarian Resources
  • Permissions
  • Terms and Conditions

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire